SITC Resource Library

The Society for Immunotherapy of Cancer (SITC) hosted the Primer on Tumor Immunology and Cancer Immunotherapy™ during the 39^th Annual Meeting & Pre-Conference Programs on November 7, 2024. Available here are the presentation slides and video from Session II: Tumor Microenvironment” as permitted by presenters.

Program Organizers

• Tullia C. Bruno, PhD – University of Pittsburgh
• Eric L. Smith, MD, PhD  – Dana-Farber Cancer Institute

Target Audience

The target audience for this annual, one-day educational program includes students, postdoctoral fellows and technicians from academia and industry, as well as physicians and scientists at more senior levels who wish to solidify their understanding of cancer immunology and immunotherapy, pharmacists and registered nurses. Patient advocates are also welcome to attend and learn basic concepts within the field.

Program Description

The field of cancer immunology and immunotherapy has driven novel therapeutic options for cancer patients. However, the complexity of the field continues to grow, thus, the SITC Primer on Tumor Immunology and Cancer Immunotherapy™ is designed to provide a foundation for understanding core immunology principles as they relate to basic and clinical research in immunotherapy of cancer. The Primer on Tumor Immunology and Cancer Immunotherapy™ will also touch on emerging therapies and technologies to ensure attendees at all levels stay updated in our expanding field, while also laying a comprehensive foundational base for all SITC attendees. 

Learning Objectives

At the conclusion of this activity, participants should be able to:

• Describe the key principles of cancer immunology and immunotherapy in the context of the cancer immunity cycle
• Review current approaches to immunotherapy including immune checkpoint blockade, vaccines, CAR-T cells, CAR-NK cells, activation of myeloid cells, modulation of tumor metabolism, T/NK cell adoptive transfer, and T cell bispecific therapies
• Outline immune monitoring techniques as well as biomarker strategies and their role in trial design and patient selection
  
• Enhance scientific exchange with colleagues and collaborators on research and application of cancer immunotherapies to improve outcomes of patients with cancer 

To view the entire program schedule (including presenter permission to post) please click here.